Overview
Overview
Speaker
speakers
Overview
sciextext
text-left
With increasing complexity of novel biopharmaceuticals comes new challenges in developing stable cell lines to produce these treatments. Strategies to gain more information on critical post translational modifications in early development can significantly accelerate drug development timelines.
- How to utilize icIEF-UV/MS to identify sequence variants
- How this information can be used to create a mitigation strategy
- What more information in less time means to groups throughout process development
sciextext
text-left
Presented by:
speakers
Kristen Nields PhD
Principal Scientist
J&J Innovative Medicines